An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Public ClinicalTrials.gov record NCT05887609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
Study identification
- NCT ID
- NCT05887609
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Colorado, Denver
- Other
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- Mirvetuximab Soravtansine-gynx Drug
- Olaparib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2, 2023
- Primary completion
- Jan 30, 2029
- Completion
- Jan 30, 2031
- Last update posted
- Apr 12, 2026
2023 – 2031
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Hospital | Aurora | Colorado | 80045 | Recruiting |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | Recruiting |
| University of Pennsylvania Health System, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | Recruiting |
| UPMC Magee-Women's Hospital | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| University of Wisconsin - Carbone Cancer Center - University Hospital | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05887609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05887609 live on ClinicalTrials.gov.